145 related articles for article (PubMed ID: 22133290)
1. Systematic review of the cost-effectiveness of positron-emission tomography in staging of non--small-cell lung cancer and management of solitary pulmonary nodules.
Cao JQ; Rodrigues GB; Louie AV; Zaric GS
Clin Lung Cancer; 2012 May; 13(3):161-70. PubMed ID: 22133290
[TBL] [Abstract][Full Text] [Related]
2. Economic analyses on the use of positron emission tomography for the work-up of solitary pulmonary nodules and for staging patients with non-small-cell-lung-cancer in Italy.
Gugiatti A; Grimaldi A; Rossetti C; Lucignani G; De Marchis D; Borgonovi E; Fazio F
Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):49-61. PubMed ID: 15195004
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of positron emission tomography for the management of potentially operable non-small cell lung cancer in Quebec.
Nguyen VH; Peloquin S; Lacasse Y
Can Respir J; 2005; 12(1):19-25. PubMed ID: 15776130
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer.
Schreyögg J; Weller J; Stargardt T; Herrmann K; Bluemel C; Dechow T; Glatting G; Krause BJ; Mottaghy F; Reske SN; Buck AK
J Nucl Med; 2010 Nov; 51(11):1668-75. PubMed ID: 21051648
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of strategies introducing integrated ¹⁸F-FDG PET/CT into the mediastinal lymph node staging of non-small-cell lung cancer.
Han Y; Xiao H; Zhou Z; Yuan M; Zeng Y; Wu H; Fang Y
Nucl Med Commun; 2015 Mar; 36(3):234-41. PubMed ID: 25460305
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer.
Yap KK; Yap KS; Byrne AJ; Berlangieri SU; Poon A; Mitchell P; Knight SR; Clarke PC; Harris A; Tauro A; Rowe CC; Scott AM
Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1033-40. PubMed ID: 15875178
[TBL] [Abstract][Full Text] [Related]
7. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
Gambhir SS; Hoh CK; Phelps ME; Madar I; Maddahi J
J Nucl Med; 1996 Sep; 37(9):1428-36. PubMed ID: 8790186
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany.
Dietlein M; Weber K; Gandjour A; Moka D; Theissen P; Lauterbach KW; Schicha H
Eur J Nucl Med; 2000 Oct; 27(10):1441-56. PubMed ID: 11083532
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective.
Alzahouri K; Lejeune C; Woronoff-Lemsi MC; Arveux P; Guillemin F
Clin Radiol; 2005 Apr; 60(4):479-92. PubMed ID: 15767106
[TBL] [Abstract][Full Text] [Related]
10. Use of a decision analysis model to assess the medicoeconomic implications of FDG PET imaging in diagnosing a solitary pulmonary nodule.
Lejeune C; Al Zahouri K; Woronoff-Lemsi MC; Arveux P; Bernard A; Binquet C; Guillemin F
Eur J Health Econ; 2005 Sep; 6(3):203-14. PubMed ID: 15834623
[TBL] [Abstract][Full Text] [Related]
11. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis.
Scott WJ; Shepherd J; Gambhir SS
Ann Thorac Surg; 1998 Dec; 66(6):1876-83; discussion 1883-5. PubMed ID: 9930463
[TBL] [Abstract][Full Text] [Related]
13. 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review.
Ung YC; Maziak DE; Vanderveen JA; Smith CA; Gulenchyn K; Lacchetti C; Evans WK;
J Natl Cancer Inst; 2007 Dec; 99(23):1753-67. PubMed ID: 18042932
[TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography with CT in the evaluation of non-small cell lung cancer in populations with a high prevalence of tuberculosis.
Low SY; Eng P; Keng GH; Ng DC
Respirology; 2006 Jan; 11(1):84-9. PubMed ID: 16423207
[TBL] [Abstract][Full Text] [Related]
15. Staging non-small lung cancer with positron emission tomography: diagnostic value, impact on patient management, and cost-effectiveness.
Nosotti M; Castellani M; Longari V; Chella B; Baisi A; Rosso L; Santambrogio L
Int Surg; 2008; 93(5):278-83. PubMed ID: 19943430
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of positron emission tomography in Canada.
Sloka JS; Hollett PD
Med Sci Monit; 2005 Oct; 11(10):PH1-6. PubMed ID: 16192911
[TBL] [Abstract][Full Text] [Related]
17. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules.
Daniels CE; Lowe VJ; Aubry MC; Allen MS; Jett JR
Chest; 2007 Jan; 131(1):255-60. PubMed ID: 17218584
[TBL] [Abstract][Full Text] [Related]
18. [Cost-effectiveness of PET in the management algorithms of lung tumors: comparison of health economic data].
Dietlein M; Moka D; Weber K; Theissen P; Schicha H
Nuklearmedizin; 2001 Aug; 40(4):122-8. PubMed ID: 11556202
[TBL] [Abstract][Full Text] [Related]
19. FDG PET-CT for solitary pulmonary nodule and lung cancer: Literature review.
Groheux D; Quere G; Blanc E; Lemarignier C; Vercellino L; de Margerie-Mellon C; Merlet P; Querellou S
Diagn Interv Imaging; 2016 Oct; 97(10):1003-1017. PubMed ID: 27567555
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules.
Gould MK; Sanders GD; Barnett PG; Rydzak CE; Maclean CC; McClellan MB; Owens DK
Ann Intern Med; 2003 May; 138(9):724-35. PubMed ID: 12729427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
